$VKTX
Viking Therapeutics, Inc. Stock $vktx

$vktx Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000156459015009694 Filed on November 05, 2015

Income Statement

Concept	2015 Q3	2014 Q4	2014 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.780M	$210.0K	$360.0K
YoY Change	394.44%
% of Gross Profit
Research & Development	$2.508M	$140.0K	$790.0K
YoY Change	217.41%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$4.288M	$350.0K	$1.150M
YoY Change	272.89%
Operating Profit	-$4.288M
YoY Change
Interest Expense	-$10.31K	-$330.0K	-$25.04K
YoY Change	-58.81%
% of Operating Profit
Other Income/Expense, Net	-$448.3K	$2.080M	$887.2K
YoY Change	-150.53%
Pretax Income	-$4.740M	$1.390M	-$260.0K
YoY Change	1723.08%
Income Tax
% Of Pretax Income
Net Earnings	-$4.737M	$1.390M	-$261.8K
YoY Change	1709.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$529.6K	$157.2K	-$30.06K
COMMON SHARES
Basic Shares Outstanding	9.783M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.50M	$800.0K
YoY Change		300.0%
Cash & Equivalents	$2.140M	$755.9K	$794.4K
Short-Term Investments	$15.30M
Other Short-Term Assets	$1.400M	$0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$18.93M	$773.7K
YoY Change		286.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$80.00K	$775.00
YoY Change
Total Long-Term Assets	$80.00K	$2.269M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$18.93M	$773.7K
Total Long-Term Assets	$80.00K	$2.269M
Total Assets	$19.01M	$3.043M
YoY Change		1421.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$401.7K	$1.831M
YoY Change		1730.72%
Accrued Expenses	$1.300M	$20.30M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.900M	$300.0K
YoY Change
Total Short-Term Liabilities	$5.723M	$22.52M
YoY Change		22417.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.300M
YoY Change		550.0%
Other Long-Term Liabilities	$0.00	$1.400M
YoY Change		1300.0%
Total Long-Term Liabilities	$19.15K	$2.655M
YoY Change		784.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.723M	$22.52M
Total Long-Term Liabilities	$19.15K	$2.655M
Total Liabilities	$5.742M	$25.17M
YoY Change		6192.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.45M	-$22.14M
YoY Change
Common Stock	$53.73M	$12.93K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.27M	-$22.13M
YoY Change
Total Liabilities & Shareholders Equity	$19.01M	$3.043M
YoY Change		1421.57%

Cashflow Statement

Concept	2015 Q3	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$4.737M	$1.390M	-$261.8K
YoY Change	1709.22%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.400M	-$440.0K	-$610.0K
YoY Change	457.38%	528.57%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$3.260M
YoY Change
Cash From Investing Activities	-$3.260M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-710.0K	400.0K	520.0K
YoY Change	-236.54%	900.0%
NET CHANGE
Cash From Operating Activities	-3.400M	-440.0K	-610.0K
Cash From Investing Activities	-3.260M
Cash From Financing Activities	-710.0K	400.0K	520.0K
Net Change In Cash	-7.370M	-40.00K	-90.00K
YoY Change	8088.89%	33.33%
FREE CASH FLOW
Cash From Operating Activities	-$3.400M	-$440.0K	-$610.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2014Q4	us-gaap	Assets Current AssetsCurrent	773684
CY2015Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	19149
CY2015Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19149
CY2014Q4	us-gaap	Liabilities Liabilities	25171665
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1442629
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17827
CY2015Q3	us-gaap	Assets Current AssetsCurrent	18932251
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	2268675
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	80000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	775
CY2015Q3	us-gaap	Assets Assets	19012251
CY2014Q4	us-gaap	Assets Assets	3043134
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	401672
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1830724
CY2014Q4	vktx	Accrued License Fees Current AccruedLicenseFeesCurrent	19865863
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1103432
	us-gaap	Revenues Revenues	0
	us-gaap	Revenues Revenues	0
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2507553
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1780668
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	4288221
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4288221
CY2014Q3	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	695251
	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	-9381848
	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	-264112
CY2015Q3	us-gaap	Interest Payable Current InterestPayableCurrent	152361
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	304274
CY2015Q3	vktx	Debt Conversion Feature Liability Current DebtConversionFeatureLiabilityCurrent	2154062
CY2014Q4	vktx	Debt Conversion Feature Liability Current DebtConversionFeatureLiabilityCurrent	58742
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5722551
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22517082
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1264114
CY2014Q4	vktx	Debt Conversion Feature Liability Noncurrent DebtConversionFeatureLiabilityNoncurrent	1390469
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2654583
CY2015Q3	us-gaap	Liabilities Liabilities	5741700
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	98
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	60
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	53729783
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12866
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40454482
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22141457
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4848
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	13270551
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-22128531
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19012251
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3043134
CY2015Q3	vktx	Convertible Notes Payable Discount Current ConvertibleNotesPayableDiscountCurrent	588976
CY2014Q4	vktx	Convertible Notes Payable Discount Current ConvertibleNotesPayableDiscountCurrent	6076
CY2015Q3	vktx	Convertible Notes Payable Discount Noncurrent ConvertibleNotesPayableDiscountNoncurrent	0
CY2014Q4	vktx	Convertible Notes Payable Discount Noncurrent ConvertibleNotesPayableDiscountNoncurrent	1235886
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9783312
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9783312
CY2015Q3	us-gaap	Revenues Revenues	0
CY2014Q3	us-gaap	Revenues Revenues	0
	vktx	Change In Fair Value Of Debt Conversion Features ChangeInFairValueOfDebtConversionFeatures	-826637
	vktx	Change In Fair Value Of Debt Conversion Features ChangeInFairValueOfDebtConversionFeatures	405782
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	652986
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	263651
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-10312
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-25037
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-448323
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	887248
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-4736544
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-261801
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2733798
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	234745
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	418412
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	-38
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	-2
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2152
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	22242404
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1765253
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1384258
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7613
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4848
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4728931
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-261801
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18317873
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23273530
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.69
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.84
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8947480
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4518439
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6802169
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3982147
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	67692
	us-gaap	Share Based Compensation ShareBasedCompensation	2074004
	us-gaap	Share Based Compensation ShareBasedCompensation	5355
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1504027
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16781
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	137286
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	84727
	vktx	Increase Decrease In Accrued License Fees IncreaseDecreaseInAccruedLicenseFees	21687576
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1244495
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	240215
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5432104
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1150457
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	16033042
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	607000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-15426042
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25392500
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	614796
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179619
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	794415
	vktx	Stock Issued In Lieu Of License Fee StockIssuedInLieuOfLicenseFee	29247711
CY2014Q3	vktx	Unpaid Deferred Initial Public Offering Costs UnpaidDeferredInitialPublicOfferingCosts	1895950
	vktx	Conversion Of Notes Payable ConversionOfNotesPayable	456412
	vktx	Issuance Of Common Stock To Consultant IssuanceOfCommonStockToConsultant	28760
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion feature liability and accounting for certain commitments. Actual results could differ from those estimates.</p></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></div>
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2012-09-24
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Delaware
	us-gaap	Additional Cash And Cash Equivalent Related Text AdditionalCashAndCashEquivalentRelatedText	Three months or less
	vktx	Offering Costs Recorded As Reduction Of Proceeds Received OfferingCostsRecordedAsReductionOfProceedsReceived	3066136
CY2015Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	9783312
CY2014Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	6000000
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	8120639
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	5813187
CY2015Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	835832
CY2014Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1481561
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1318470
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1831040
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2012697
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2295833
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0
CY2015Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	16623402
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	975
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5823
CY2015Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	16618554
CY2015Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	12
CY2015Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
CY2015Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	16618554
CY2015Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	2154062
CY2014Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	21315074
CY2014Q1	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	1000000
CY2014Q1	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	0.01
CY2014Q1	vktx	Number Of Tranches NumberOfTranches	2
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	168000
CY2015Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	633810
CY2015Q2	vktx	Shares Repurchase Price Per Share SharesRepurchasePricePerShare	0.00001
CY2015Q2	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	366190
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	61566
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	0
	vktx	Anniversary Closing Date Of Initial Public Offering AnniversaryClosingDateOfInitialPublicOffering	2016-05-04
CY2015Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	282
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	601593
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	904
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2074004
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5355
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	443894
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	33750
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	410144
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	51500
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.49
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.49
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.41
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.49
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y7M28D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.25
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	84000
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.852
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y5M27D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0181
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	282
CY2015Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2015Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.00
	vktx	Description Of Warrant DescriptionOfWarrant	The warrant is exercisable for cash or on a cashless basis at a per share exercise price equal to $10.00 commencing on April 28, 2016, one year following the date of the prospectus filed with the SEC relating to the IPO, and expiring on April 28, 2020. The representative (or permitted assignees) agreed not to sell, transfer, assign, pledge or hypothecate the warrant or the shares of common stock underlying the warrant, or to engage in any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the warrant or the underlying shares of common stock until October 25, 2015. In addition, the warrant provides for registration rights upon request, under certain circumstances. The piggyback registration right provided in connection with the warrant will terminate on April 28, 2022.
	vktx	Warrant Expiration Date WarrantExpirationDate	2022-04-28
	vktx	Initial Public Offering Expiration Date InitialPublicOfferingExpirationDate	2020-04-28
CY2015Q3	vktx	Sublease Area SubleaseArea	7049
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	39474
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	199740
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	247611
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	190337
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	677162

Files In Submission

Name	View Source	Status
0001564590-15-009694-index-headers.html	Edgar Link	pending
0001564590-15-009694-index.html	Edgar Link	pending
0001564590-15-009694.txt	Edgar Link	pending
0001564590-15-009694-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g201511052101122731601.jpg	Edgar Link	pending
g201511052101123511602.jpg	Edgar Link	pending
g201511052101139911603.jpg	Edgar Link	pending
g201511052101150071604.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vktx-10q_20150930.htm	Edgar Link	pending
vktx-20150930.xml	Edgar Link	completed
vktx-20150930.xsd	Edgar Link	pending
vktx-20150930_cal.xml	Edgar Link	unprocessable
vktx-20150930_def.xml	Edgar Link	unprocessable
vktx-20150930_lab.xml	Edgar Link	unprocessable
vktx-20150930_pre.xml	Edgar Link	unprocessable
vktx-ex101_298.htm	Edgar Link	pending
vktx-ex311_6.htm	Edgar Link	pending
vktx-ex312_7.htm	Edgar Link	pending
vktx-ex321_8.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VKTX
Viking Therapeutics, Inc. Stock $vktx

2015 Q3 Form 10-Q Financial Statement

#000156459015009694 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VKTX Viking Therapeutics, Inc. Stock $vktx

2015 Q3 Form 10-Q Financial Statement

#000156459015009694 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VKTX
Viking Therapeutics, Inc. Stock $vktx